Weekly Digest - Feb 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - Feb 2024
15 Feb 2024: Lantern Pharma progresses novel ADC program in various solid tumors
- Lantern has advanced the development, synthesis, and preclinical POC of a novel, highly potent, cryptophycin-based ADC
- The company has leveraged RADR, a proprietary AI platform for target selection and molecular payload characterization in ADCs, and a unique, controlled conjugation approach for maximizing DAR ratios while controlling for non-specific conjugation
- Lantern expects to move towards IND development of the ADC program during 2024 with a focus on select solid tumors that are unresponsive or refractory to current therapies
- ADCs, a promising cancer therapy class, are projected to surpass $24 billion in revenue by 2030. Recent M&A activity reflects their importance, with both emerging biotechs and global pharmaceutical companies heavily involved
